
Janssen-Cilag International gets European Commission nod for subcutaneous Rybrevant for advanced EGFR-mutated non-small ...
Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) for an extension of marketing authorisation for a subcutaneous (SC) formulation of RYBREVANT (amivantamab), in combination with …